title: Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.
abstract: The exposure of calreticulin (CRT) on the surface of stressed and dying cancer cells facilitates their uptake by dendritic cells and the subsequent presentation of tumor-associated antigens to T lymphocytes, hence stimulating an anticancer immune response. The chemotherapeutic agent mitoxantrone (MTX) can stimulate the peripheral relocation of CRT in both human and yeast cells, suggesting that the CRT exposure pathway is phylogenetically conserved. Here, we show that pheromones can act as physiological inducers of CRT exposure in yeast cells, thereby facilitating the formation of mating conjugates, and that a large-spectrum inhibitor of G protein-coupled receptors (which resemble the yeast pheromone receptor) prevents CRT exposure in human cancer cells exposed to MTX. An RNA interference screen as well as transcriptome analyses revealed that chemokines, in particular human CXCL8 (best known as interleukin-8) and its mouse ortholog Cxcl2, are involved in the immunogenic translocation of CRT to the outer leaflet of the plasma membrane. MTX stimulated the production of CXCL8 by human cancer cells in vitro and that of Cxcl2 by murine tumors in vivo. The knockdown of CXCL8/Cxcl2 receptors (CXCR1/Cxcr1 and Cxcr2) reduced MTX-induced CRT exposure in both human and murine cancer cells, as well as the capacity of the latter-on exposure to MTX-to elicit an anticancer immune response in vivo. Conversely, the addition of exogenous Cxcl2 increased the immunogenicity of dying cells in a CRT-dependent manner. Altogether, these results identify autocrine and paracrine chemokine signaling circuitries that modulate CRT exposure and the immunogenicity of cell death.
authors.affiliation: 1] INSERM, U848, Villejuif, France [2] Institut Gustave Roussy, Villejuif, France [3] Université Paris Sud/Paris XI, Le Kremlin Bicêtre, France.
authors.forename: A Q
authors.initials: AQ
authors.lastname: Sukkurwala
authors.forename: I
authors.initials: I
authors.lastname: Martins
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: F
authors.initials: F
authors.lastname: Schlemmer
authors.forename: C
authors.initials: C
authors.lastname: Ruckenstuhl
authors.forename: M
authors.initials: M
authors.lastname: Durchschlag
authors.forename: M
authors.initials: M
authors.lastname: Michaud
authors.forename: L
authors.initials: L
authors.lastname: Senovilla
authors.forename: A
authors.initials: A
authors.lastname: Sistigu
authors.forename: Y
authors.initials: Y
authors.lastname: Ma
authors.forename: E
authors.initials: E
authors.lastname: Vacchelli
authors.forename: E
authors.initials: E
authors.lastname: Sulpice
authors.forename: X
authors.initials: X
authors.lastname: Gidrol
authors.forename: L
authors.initials: L
authors.lastname: Zitvogel
authors.forename: F
authors.initials: F
authors.lastname: Madeo
authors.forename: L
authors.initials: L
authors.lastname: Galluzzi
authors.forename: O
authors.initials: O
authors.lastname: Kepp
authors.forename: G
authors.initials: G
authors.lastname: Kroemer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D037282:Calreticulin / Q000378:metabolism*; D045744:Cell Line, Tumor; D054426:Chemokine CXCL2 / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D045325:HCT116 Cells; D006367:HeLa Cells; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008942:Mitoxantrone / Q000627:therapeutic use / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D023062:Receptors, Interleukin-8A / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D023063:Receptors, Interleukin-8B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000145:classification / Q000378:metabolism; D029701:Saccharomyces cerevisiae Proteins / Q000378:metabolism*; D015398:Signal Transduction; D059467:Transcriptome / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D037282:Calreticulin; D054426:Chemokine CXCL2; D016209:Interleukin-8; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; D029701:Saccharomyces cerevisiae Proteins; D008942:Mitoxantrone